dalteparin and Angina at Rest studies

Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)

Research Excerpts

Excerpt	Relevance	Reference
"Patients with high-risk non-ST-segment elevation acute coronary syndromes (NSTE ACS) benefit from the early administration of aspirin, a small molecule glycoprotein IIb/IIIa inhibitor such as eptifibatide, and heparin."	9.12	Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin ( Armstrong, PW; Fitchett, DH; Goodman, SG; Langer, A; Mendelsohn, A; Tan, M, 2006)
"The OASIS-5 trial was a double-blind, randomized comparison of fondaparinux and enoxaparin in 20,078 patients with acute coronary syndrome."	9.12	Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. ( Afzal, R; Bassand, JP; Budaj, A; Chrolavicius, S; Eikelboom, JW; Faxon, DP; Fox, KA; Granger, CB; Mehta, SR; Peters, RJ; Wallentin, L; Yusuf, S, 2007)
"In non-ST-elevation acute coronary syndrome, there was a simultaneous activation of the inflammation, coagulation, and fibrinolysis systems, despite aspirin and dalteparin treatment."	9.11	Activation of the inflammation, coagulation, and fibrinolysis systems, without influence of abciximab infusion in patients with non-ST-elevation acute coronary syndromes treated with dalteparin: a GUSTO IV substudy. ( Armstrong, P; Barnathan, E; Califf, R; James, SK; Siegbahn, A; Simoons, ML; Wallentin, L, 2004)
"The low-molecular-weight heparins (LMWHs) enoxaparin and dalteparin have shown superior and equivalent efficacy, respectively, over unfractionated heparin (UFH) in patients with unstable angina pectoris (UAP) or non-ST-segment elevation myocardial infarction (NSTEMI)."	9.10	Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study). ( Bal-dit-Sollier, C; Chibedi, D; Choussat, R; Cohen, A; Collet, JP; Dalby, M; Drouet, L; Dubois-Randé, JL; Guermonprez, JL; Metzger, JP; Montalescot, G; Slama, M; Soulat, T; Steg, PG; Tarragano, F, 2003)
"The rate of death, myocardial infarction, and urgent revascularization at days 8 and 43 after randomization was compared among patients who received aspirin within the week before randomization with those who did not receive aspirin in the TIMI 11B trial."	9.09	Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin. ( Antman, EM; Bozovich, GE; Gurfinkel, EP; Marcos, E; Mautner, B; McCabe, CH; Santopinto, J; Torres, V, 2001)
"Fifty-five patients with non-Q-wave myocardial infarction were randomized to receive double-blind treatment with tirofiban (0."	9.09	Combination therapy with tirofiban and enoxaparin in acute coronary syndromes. ( Borzak, S; Cohen, M; Deckelbaum, LI; Diodati, JG; Harris, KE; Huynh, T; Laramée, P; Lo, MW; Sax, FL; Squire, IB; Théroux, P; Thornton, AR; Weber, S; White, HD, 1999)
"The mainstay of treatment for unstable coronary artery disease (UCAD) currently consists of antithrombotic therapy with aspirin plus unfractionated heparin (UFH), together with anti-ischemic treatment with beta blockers and nitrates."	6.19	Long-term management--the way forward? ( Wallentin, L, 2000)
"Fondaparinux is similar to enoxaparin in reducing the risk of ischemic events at nine days, but it substantially reduces major bleeding and improves long term mortality and morbidity."	5.12	Comparison of fondaparinux and enoxaparin in acute coronary syndromes. ( Afzal, R; Bassand, JP; Budaj, A; Chrolavicius, S; Fox, KA; Granger, CB; Joyner, C; Mehta, SR; Peters, RJ; Pogue, J; Wallentin, L; Yusuf, S, 2006)
"Patients with high-risk non-ST-segment elevation acute coronary syndromes (NSTE ACS) benefit from the early administration of aspirin, a small molecule glycoprotein IIb/IIIa inhibitor such as eptifibatide, and heparin."	5.12	Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin ( Armstrong, PW; Fitchett, DH; Goodman, SG; Langer, A; Mendelsohn, A; Tan, M, 2006)
"The OASIS-5 trial was a double-blind, randomized comparison of fondaparinux and enoxaparin in 20,078 patients with acute coronary syndrome."	5.12	Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. ( Afzal, R; Bassand, JP; Budaj, A; Chrolavicius, S; Eikelboom, JW; Faxon, DP; Fox, KA; Granger, CB; Mehta, SR; Peters, RJ; Wallentin, L; Yusuf, S, 2007)
"In patients with moderate- or high-risk acute coronary syndromes who were undergoing invasive treatment with glycoprotein IIb/IIIa inhibitors, bivalirudin was associated with rates of ischemia and bleeding that were similar to those with heparin."	5.12	Bivalirudin for patients with acute coronary syndromes. ( Aylward, PE; Bertrand, ME; Cequier, AR; Colombo, A; Cox, DA; Darius, H; Desmet, W; Ebrahimi, R; Feit, F; Hamon, M; Hoekstra, J; Lincoff, AM; McLaurin, BT; Mehran, R; Moses, JW; Ohman, EM; Pocock, SJ; Rasmussen, LH; Rupprecht, HJ; Stone, GW; Ware, JH; White, HD, 2006)
"The goal of this study was to evaluate glycoprotein IIb/IIIa inhibition with eptifibatide when administered with indirect thrombin inhibition as compared with monotherapy with direct thrombin inhibition with bivalirudin among patients with non-ST-segment elevation acute coronary syndromes (ACS)."	5.12	A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial. ( Braunwald, E; Bulle, T; Cohen, DJ; Fish, P; Gibson, CM; Jennings, LK; Kovach, R; Lakkis, N; Lui, HH; McCabe, CH; Morrow, DA; Murphy, SA; Palabrica, TM; Stone, PH, 2006)
"In non-ST-elevation acute coronary syndrome, there was a simultaneous activation of the inflammation, coagulation, and fibrinolysis systems, despite aspirin and dalteparin treatment."	5.11	Activation of the inflammation, coagulation, and fibrinolysis systems, without influence of abciximab infusion in patients with non-ST-elevation acute coronary syndromes treated with dalteparin: a GUSTO IV substudy. ( Armstrong, P; Barnathan, E; Califf, R; James, SK; Siegbahn, A; Simoons, ML; Wallentin, L, 2004)
"The OASIS-5 trial is a randomized, double-blind trial of fondaparinux versus enoxaparin in 20,000 patients with unstable angina or non-ST-segment elevation myocardial infarction."	5.11	Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes. ( Bassand, JP; Budaj, A; Chrolavicius, S; Fox, KA; Granger, CB; Joyner, C; Mehta, SR; Peters, RJ; Wallentin, L; Yusuf, S, 2005)
"The low-molecular-weight heparins (LMWHs) enoxaparin and dalteparin have shown superior and equivalent efficacy, respectively, over unfractionated heparin (UFH) in patients with unstable angina pectoris (UAP) or non-ST-segment elevation myocardial infarction (NSTEMI)."	5.10	Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study). ( Bal-dit-Sollier, C; Chibedi, D; Choussat, R; Cohen, A; Collet, JP; Dalby, M; Drouet, L; Dubois-Randé, JL; Guermonprez, JL; Metzger, JP; Montalescot, G; Slama, M; Soulat, T; Steg, PG; Tarragano, F, 2003)
"The FRISC II study addressed two key questions in the management of acute coronary syndromes: is it beneficial to extend low-molecular-weight heparin (LMWH) therapy with dalteparin beyond the initial period of acute treatment; and, is a strategy of early invasive therapy, including angioplasty and surgical revascularization, preferable to a more conservative strategy? The study focused on patients with unstable coronary artery disease (UCAD), that is, angina and non-ST-segment-elevation myocardial infarction (MI)."	5.09	Improving outcomes in acute coronary syndromes--the FRISC II trial. ( Kontny, F, 2001)
"Fifty-five patients with non-Q-wave myocardial infarction were randomized to receive double-blind treatment with tirofiban (0."	5.09	Combination therapy with tirofiban and enoxaparin in acute coronary syndromes. ( Borzak, S; Cohen, M; Deckelbaum, LI; Diodati, JG; Harris, KE; Huynh, T; Laramée, P; Lo, MW; Sax, FL; Squire, IB; Théroux, P; Thornton, AR; Weber, S; White, HD, 1999)
"The rate of death, myocardial infarction, and urgent revascularization at days 8 and 43 after randomization was compared among patients who received aspirin within the week before randomization with those who did not receive aspirin in the TIMI 11B trial."	5.09	Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin. ( Antman, EM; Bozovich, GE; Gurfinkel, EP; Marcos, E; Mautner, B; McCabe, CH; Santopinto, J; Torres, V, 2001)
"Enoxaparin, a low-molecular-weight heparin, and tirofiban, an intravenous platelet glycoprotein IIb/IIIa receptor antagonist, have each been shown to be effective in reducing cardiac ischemic events compared to unfractionated heparin alone in separate trials of patients with unstable angina and non-Q wave myocardial infarction."	5.09	Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes. ( Cohen, M, 2000)
"Long-term dalteparin lowers the risk of death, myocardial infarction, and revascularisation in unstable coronary-artery disease at least during the first month of therapy."	5.09	Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease. Investigators. ( , 1999)
"The safety and efficacy of weight-adjusted, low-molecular-weight heparin (dalteparin) was compared with that of unfractionated heparin during 6 days of treatment in 1,482 patients with unstable angina or non-Q-wave myocardial infarction."	5.08	Fragmin in unstable angina pectoris or in non-Q-wave acute myocardial infarction (the FRIC study). Fragmin in Unstable Coronary Artery Disease. ( Buchwald, A; Hillis, WS; Klein, W; Ludwig, K; Monrad, S; Olaisson, E; Sanz, G; Turpie, AG; Undeland, S; van der Meer, J, 1997)
"Antithrombotic therapy with enoxaparin plus aspirin was more effective than unfractionated heparin plus aspirin in reducing the incidence of ischemic events in patients with unstable angina or non-Q-wave myocardial infarction in the early phase."	5.08	A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. ( Bigonzi, F; Califf, RM; Cohen, M; Demers, C; Fox, KA; Fromell, GJ; Goodman, S; Gurfinkel, EP; Langer, A; Premmereur, J; Turpie, AG, 1997)
"During the first 6 days the rate of death and new myocardial infarction was lower in the dalteparin group than in the placebo group (13 [1."	5.08	Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group. ( , 1996)
"Our results add to previous evidence suggesting that the low-molecular-weight heparin dalteparin administered by twice-daily subcutaneous injection may be an alternative to unfractionated heparin in the acute treatment of unstable angina or non-Q-wave myocardial infarction."	5.08	Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC) ( Buchwald, A; Hillis, SE; Klein, W; Ludwig, K; Monrad, S; Olaisson, E; Sanz, G; Turpie, AG; Undeland, S; van der Meer, J, 1997)
"Antithrombotic and antiplatelet agents, particularly unfractionated heparin and aspirin, are longstanding therapeutic mainstays for acute coronary syndromes such as unstable angina and non-Q-wave myocardial infarction (MI)."	4.80	Anticoagulants in acute coronary syndromes. ( Turpie, AG, 1999)
"Treatment with dalteparin reduced the risk of death and myocardial infarction in high-risk (i."	3.79	Low-molecular-weight heparin as a bridge to timely revascularization in unstable coronary artery disease -- an update of the Fragmin during Instability in Coronary Artery Disease II Trial. ( Wallentin, L, 2000)
" In early trials, such as FRISC (Fragmin during instability in coronary artery disease) and FRIC (Fragmin in unstable coronary artery disease), the results of extended treatment were inconclusive; however, the trial populations included patients of relatively low risk and used a once-daily dosing regimen."	3.79	Acute and prolonged treatment with low-molecular-weight heparin therapy in patients with unstable coronary artery disease. ( Husted, S; Kher, A, 2000)
"The current standard of care for patients with non-ST-segment elevation acute coronary syndromes (ACS) includes antithrombotic therapy with aspirin and heparin."	3.71	Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. ( Antman, EM; Ball, SP; Becker, RC; Gibson, M; Murphy, SA; Rush, JE; Sanderink, G; Spencer, FA, 2002)
"(1) Aspirin reduces acute-phase mortality after myocardial infarction, and also reduces the risk of myocardial infarction and death in patients with unstable angina."	3.70	Antiplatelet drugs in cardiovascular prevention: coronary events: acute phase and secondary prevention. ( , 2000)
"In 256 patients participating in the FRISC trial, evaluating the effects of dalteparin (a low molecular weight heparin) in unstable angina or non-Q wave myocardial infarction, Chlamydia pneumoniae IgA antibody titres and levels of fibrinogen, C-reactive protein and troponin T were determined at inclusion."	3.70	Increased fibrinogen levels are associated with persistent Chlamydia pneumoniae infection in unstable coronary artery disease. ( Gnarpe, H; Gnarpe, J; Lindahl, B; Siegbahn, A; Toss, H; Wallentin, L, 1998)
"(1) Enoxaparin and dalteparin are the only low-molecular-weight heparins so far approved for the treatment of unstable angina and non Q-wave myocardial infarction."	3.70	Enoxaparin and dalteparin in unstable angina: new indication. Enoxaparin: a reference treatment. Dalteparin: no better than unfractionated heparin. ( , 1999)
" Adverse events were similar in the three groups."	2.72	A randomized controlled clinical trial to evaluate the efficacy, safety, cost-effectiveness and effect on PAI-1 levels of the three low-molecular-weight heparins--enoxaparin, nadroparin and dalteparin. The ESCAPe-END study. ( Bhalla, A; Grover, A; Malhotra, S; Pandhi, P; Shafiq, N; Sharma, N, 2006)
" A population pharmacokinetic analysis was conducted and individual estimates of enoxaparin clearance and area under the curve were tested as prognostic factors for the occurrence of haemorrhagic episodes."	2.71	Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non-ST-segment elevation myocardial infarction. ( Antman, EM; Baille, P; Becker, R; Bruno, R; Retout, S; Sanderink, GJ; Veyrat-Follet, C; Vivier, N, 2003)
"Pain was assessed with a 10-unit numeric scale."	2.70	Comparison of two needle sizes for subcutaneous administration of enoxaparin: effects on size of hematomas and pain on injection. ( Kanji, Z; Robb, DM, 2002)
"The dosage of the subcutaneous low molecular weight heparin enoxaparin in unstable angina patients undergoing coronary angiogram and coronary angioplasty depends clearly on the renal function."	2.70	Enoxaparin in unstable angina patients with renal failure. ( Ankri, A; Choussat, R; Collet, JP; Lison, L; Montalescot, G, 2001)
"Patients with unstable angina pectoris (UAP) or non-ST-segment elevation acute myocardial infarction (AMI) are at risk of death or recurrent ischemic events, despite receiving aspirin and unfractionated heparin (UFH)."	2.70	Prospective comparison of hemorrhagic complications after treatment with enoxaparin versus unfractionated heparin for unstable angina pectoris or non-ST-segment elevation acute myocardial infarction. ( Berkowitz, SD; Bigonzi, F; Cohen, M; Fromell, GJ; Stinnett, S, 2001)
" Due to the greater bioavailability and longer half-life of Fragmin compared with conventional heparin we postulated that this may influence postoperative bleeding after cardiac surgery for unstable angina."	2.69	Effect of low molecular weight heparin (fragmin) on bleeding after cardiac surgery. ( Clark, SC; Forty, J; Vitale, N; Zacharias, J, 2000)
"In dalteparin-treated patients, delta vWf was elevated (+48 +/- 8%) and did not differ from the unfractionated heparin group (NS)."	2.69	Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. ( Ankri, A; Choussat, R; Collet, JP; Drobinski, G; Lison, L; Montalescot, G; Perlemuter, K; Philippe, F; Thomas, D; Vicaut, E, 2000)
" UFH is limited due to its unpredictable antithrombotic effect, poor bioavailability when given subcutaneously, requirement for hospitalization and need for frequent laboratory monitoring."	2.69	Management of acute coronary syndromes with low molecular weight heparin: TIMI 11A and 11B. ( Turpie, AG, 1998)
"Fondaparinux has been shown to be as effective as enoxaparin in the prevention of thrombosis in patients undergoing orthopedic surgery and showed similar results compared to enoxaparin or UFH in patients with deep-vein-thrombosis or pulmonary embolism."	2.44	Factor Xa inactivation in acute coronary syndrome. ( Barantke, M; Bonnemeier, H, 2008)
" Careful attention to dosing and excellent vascular access site management after cardiac catheterization are required to decrease the risk of bleeding and blood transfusion, which have been associated with increased mortality risk."	2.44	New anticoagulant options for ST-elevation myocardial infarction and unstable angina pectoris/non-ST-elevation myocardial infarction. ( Bates, ER, 2007)
" Unlike its unfractionated heparin (UFH) counterparts, enoxaparin has a greater bioavailability, lower incidence of heparin-induced thrombocytopenia and more stable and predictable anticoagulation, allowing fixed dosing without the need for monitoring."	2.44	Enoxaparin in acute coronary syndromes. ( Gibson, CM; Lee, S, 2007)
" Future issues that need to be addressed include refinement of indications for administration and patient selection, comparison between existing agents, evaluation of newer agents, and optimization of dosing to maximize benefit and safety in the use of these powerful new classes of drugs."	2.41	Glycoprotein IIb/IIIa antagonists and low-molecular weight heparin in acute coronary syndromes. ( Vernon, SM, 2001)
" Compared to unfractionated heparins LMWH are user-friendly (high bioavailability after subcutaneous application, no needed routine control of plasma efficacy)."	2.41	[Low molecular weight heparins in acute coronary syndrome]. ( Huber, K; Niessner, A; Niessner, H, 2001)
"Patients presenting with unstable angina pectoris or non-Q-wave myocardial infarction (MI), if treated inadequately, are at a high risk of MI and subsequent mortality."	2.41	Current management of unstable angina: lessons from the TACTICS-TIMI 18 trial. ( Adgey, AA; Manoharan, G, 2002)
"Unstable angina is in most cases caused by partial or complete coronary artery occlusion due to the disruption of an atherosclerotic plaque and to thrombus formation."	2.41	Therapy of unstable angina with the low molecular weight heparins. ( Ageno, W; Turpie, AG, 2000)
"Unstable angina is in most cases caused by partial or complete coronary artery occlusion due to the disruption of an atherosclerotic plaque and resultant thrombus formation."	2.41	Low molecular weight heparins in the treatment of unstable angina. ( Ageno, W; Turpie, AG, 2002)
" They are more predictable in action, do not require frequent activated partial thromboplastin time (aPTT) measurements and dosage adjustments, are easier to administer, and are potentially more efficacious."	2.41	Role of low-molecular-weight heparins in the management of patients with unstable angina pectoris and non-Q-wave acute myocardial infarction. ( Monrad, ES, 2000)
"However, for most patients with congestive heart failure (who will be at bedrest initially), DVT prophylaxis may be the only indication for anticoagulation."	2.41	Deep venous thrombosis prophylaxis in patients with heart disease. ( Shively, BK, 2001)
" Low-molecular-weight heparin provides more reliable anticoagulation and less need for patient monitoring and dosage adjustment than standard unfractionated heparin (UFH) and therefore is well suited for long-term anticoagulation on an outpatient basis."	2.40	TIMI 11B. Enoxaparin versus unfractionated heparin for unstable angina or non-Q-wave myocardial infarction: a double-blind, placebo-controlled, parallel-group, multicenter trial. Rationale, study design, and methods. Thrombolysis in Myocardial Infarction ( Antman, EM, 1998)
" However total rate of all adverse events after PCI turned out to be minimal (7."	1.35	[Efficacy and safety of enoxaparin use during drug-eluting stents implantation]. ( Batyraliev, TA; Dolgikh, NN; Kadyrov, BK; Lazarev, IA; Mustafaoglu, F; Pershukov, IV; Petrakova, LN; Pia, IuV; Ramazanov, DM; Sal'nikov, DV; Shul'zhenko, LV; Sidorenko, BA, 2008)
"Fondaparinux was found to be noninferior to enoxaparin and was associated with fewer bleeding events in the OASIS-5 study of patients who were not treated with an early invasive approach."	1.35	2007 Guideline update for unstable angina/non-ST-segment elevation myocardial infarction: focus on antiplatelet and anticoagulant therapies. ( Battistone, S; Coons, JC, 2008)
"To evaluate how enoxaparin is dosed in contemporary clinical practice as a function of patients' total body weight (TBW) and body mass index (BMI), and to determine any association between dose and major bleeding."	1.35	Weight-based dosing of enoxaparin in obese patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE initiative. ( Alexander, KP; Gibler, WB; Ohman, EM; Ou, FS; Peterson, ED; Pollack, CV; Roe, MT; Spinler, SA, 2009)
" However, little dosing information is available regarding the use of enoxaparin in patients with renal impairment."	1.33	Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome. ( Ankri, A; Collet, JP; Hulot, JS; Lechat, P; Montalescot, G; Urien, S, 2005)
"The following is a case of fat necrosis due to low-molecular-weight heparin in a 91-year-old woman admitted to hospital with unstable angina."	1.33	Low-molecular-weight heparin-associated fat necrosis of the breast. ( Das, AK, 2005)
" Enoxaparin dosing practices, factors that might influence the safety of enoxaparin administration, and bleeding events were documented."	1.32	Dosing practices and risk factors for bleeding in patients receiving enoxaparin for the treatment of an acute coronary syndrome. ( Douketis, JD; Forbes, L; Foster, GA; Macie, C, 2004)
"Subcutaneous Enoxaparin given at least for 48 hours before PCI with out additional UFH or LMWH during or after PCI was both safe and effective in high risk UA/NQMI patients."	1.32	[The safety and efficacy of pre-treatment with enoxaparin (Clexane) in acute coronary syndrome patients undergoing percutaneous coronary intervention]. ( Chen, BX; Hu, DY; Jia, SQ; Kong, FL; Li, TC; Wang, L; Zhao, H; Zhao, XL, 2003)
"An 84-year-old woman with unstable angina pectoris was treated with subcutaneous enoxaparine (Clexane) for several days before presenting with severe pain and decreased vision in her left eye."	1.31	Massive choroidal hemorrhage associated with low molecular weight heparin therapy. ( Goldstein, M; Leibovitch, I; Loewenstein, A; Neudorfer, M, 2002)

Research

Studies (182)

Authors

Clinical Trials (16)

Trial Overview

Trial Outcomes

Composite of Death, MI, Stroke, Refractory Ischemia or Repeat Revascularization at 180 Days

Composite of Death, Myocardial (re-) Infarction, or Stroke

First Occurrence of Any Component of the Composite of Death, MI, or Refractory Ischemia

Acute Coronary Syndrome

Length of Stay

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	48 (26.37)	18.2507
2000's	131 (71.98)	29.6817
2010's	3 (1.65)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Ageno, W	2
Turpie, AG	11
Bassand, JP	4
Berthe, C	1
Bethencourt, A	1
Bolognese, L	1
Wójcik, J	1
Okmen, E	1
Ozen, E	1
Uyarel, H	1
Sanli, A	1
Tartan, Z	1
Cam, N	1
Shafiq, N	1
Malhotra, S	1
Pandhi, P	1
Sharma, N	1
Bhalla, A	1
Grover, A	1
Timofeeva, AV	1
Dobrotvorskaia, TE	1
Dolgov, VV	1
Arifullin, ShS	1
Talley, JD	1
Godoy, I	1
Herrera, C	1
Zapata, C	1
Kunstmann, S	1
Abufhele, A	1
Corbalán, R	2
Panchenko, EP	1
Zed, PJ	2
Tisdale, JE	1
Borzak, S	2
Antman, EM	17
Cohen, M	21
Radley, D	4
McCabe, C	2
Rush, J	1
Premmereur, J	4
Braunwald, E	11
Kaul, S	1
Shah, PK	1
Borja, J	3
Olivella, P	2
Goldmann, BU	1
Hamm, CW	1
Huber, K	2
Niessner, A	1
Niessner, H	1
Vernon, SM	1
Ramos-Esquivel, A	1
Salazar-Sánchez, L	1
Mayer, M	1
Coons, JC	1
Battistone, S	1
Mustafaoglu, F	1
Petrakova, LN	1
Pershukov, IV	1
Batyraliev, TA	1
Pia, IuV	1
Lazarev, IA	1
Ramazanov, DM	1
Shul'zhenko, LV	1
Kadyrov, BK	1
Sal'nikov, DV	1
Dolgikh, NN	1
Sidorenko, BA	1
Spinler, SA	3
Ou, FS	1
Roe, MT	1
Gibler, WB	2
Ohman, EM	2
Pollack, CV	1
Alexander, KP	1
Peterson, ED	1
Damman, P	1
Hirsch, A	1
Windhausen, F	1
Tijssen, JG	2
de Winter, RJ	1
Fox, KA	12
Bigonzi, F	5
Robb, DM	1
Kanji, Z	1
Jones, HU	1
Muhlestein, JB	1
Jones, KW	1
Bair, TL	1
Lavasani, F	1
Sohrevardi, M	1
Horne, BD	1
Doty, D	1
Lappe, DL	1
Aslam, MS	1
Sundberg, S	1
Sabri, MN	1
Cooke, D	1
Lakier, JB	1
Ozdemir, M	1
Erdem, G	1
Türkoglu, S	1
Cemri, M	1
Timurkaynak, T	1
Boyaci, B	1
Ridvan, Y	1
Cengel, A	1
Dörtlemez, O	1
Dörtlemez, H	1
Collet, JP	8
Montalescot, G	11
Fine, E	1
Golmard, JL	2
Dalby, M	2
Choussat, R	7
Ankri, A	8
Dumaine, R	2
Lesty, C	1
Vignolles, N	2
Thomas, D	6
Gerotziafas, GT	1
Zafiropoulos, A	1
Van Dreden, P	1
Karavaggeli, E	1
Goutzoumas, N	1
Nikolaidis, P	1
Combot, C	1
Lagoudaki, P	1
Zervas, K	1
Arzoglou, P	1
Samama, MM	2
Durrleman, S	1
Chaikin, P	1
Monroe, VS	1
Kerensky, RA	1
Rivera, E	1
Smith, KM	1
Pepine, CJ	2
Ortega-Carnicer, J	1
Ceres, F	1
White, RH	1
Ginsberg, JS	1
Bal-dit-Sollier, C	1
Chibedi, D	1
Soulat, T	1
Cohen, A	1
Slama, M	1
Steg, PG	2
Dubois-Randé, JL	1
Metzger, JP	1
Tarragano, F	1
Guermonprez, JL	1
Drouet, L	1
Hu, DY	1
Zhao, XL	1
Jia, SQ	1
Li, TC	1
Wang, L	1
Zhao, H	1
Kong, FL	1
Chen, BX	1
Michalis, LK	2
Katsouras, CS	1
Papamichael, N	2
Adamides, K	2
Naka, KK	2
Goudevenos, J	1
Sideris, DA	2
Bijsterveld, NR	2
Moons, AH	2
Meijers, JC	2
Levi, M	2
Büller, HR	2
Peters, RJ	5
Bruno, R	1
Baille, P	1
Retout, S	1
Vivier, N	1
Veyrat-Follet, C	1
Sanderink, GJ	1
Becker, R	1
Ferguson, JJ	4
Bates, ER	3
Every, NR	1
Harrington, RA	3
Theroux, P	4
Bosanquet, N	1
Jönsson, B	1
Tanguy, ML	2
Beygui, F	2
Drobinski, G	3
Macie, C	1
Forbes, L	1
Foster, GA	1
Douketis, JD	1
Gratsianskiĭ, NA	1
Alesh De Konto, A	1
Zuniga, MA	1
Enar, R	1
Akhmed Sheĭkh, C	1
Makarie, K	1
Petersen, JL	2
Mahaffey, KW	3
Hasselblad, V	1
Goodman, SG	9
Langer, A	7
Blazing, MA	1
Le-Moigne-Amrani, A	1
de Lemos, JA	3
Nessel, CC	2
Califf, RM	6
Das, P	1
Moliterno, DJ	1
Payot, L	1
Gallois, V	1
Becker, RC	3
Kleiman, NS	2
Marian, AJ	1
Stone, GW	3
Lansky, AJ	2
Lincoff, AM	3
Hazen, SL	1
Toro-Figueroa, L	1
Tate, L	1
Reist, CJ	1
Bertrand, M	1
Colombo, A	2
Dangas, G	1
Farkouh, ME	1
Feit, F	2
Mehran, R	2
Moses, JW	2
Ohman, M	1
White, HD	5
Quiles, J	1
Avanzas, P	1
Bueno, H	1
Das, AK	1
Fitchett, D	1
Welsh, R	1
Goodman, S	2
Dobesh, P	1
Galla, JM	1
Hulot, JS	1
Lechat, P	1
Urien, S	1
Katsouras, C	1
Nikas, D	1
Goudevenos, JA	1
Mehta, SR	3
Yusuf, S	4
Granger, CB	5
Wallentin, L	19
Budaj, A	4
Joyner, C	2
Chrolavicius, S	3
Buckmaster, ND	1
Heazlewood, V	1
Scott, IA	1
Jones, M	1
Haerer, W	1
Hillier, K	1
Fitchett, DH	1
Armstrong, PW	3
Tan, M	2
Mendelsohn, A	1
Husedzinov, I	1
Bradic, N	1
Nikic, N	1
Barisin, S	1
Desnica, M	1
Afzal, R	2
Pogue, J	1
Gibbons, RJ	1
Fuster, V	2
Bozovich, GE	3
Dos Santos, A	1
Gurfinkel, EP	8
Gibson, CM	2
Morrow, DA	3
Murphy, SA	3
Palabrica, TM	1
Jennings, LK	1
Stone, PH	1
Lui, HH	1
Bulle, T	1
Lakkis, N	1
Kovach, R	1
Cohen, DJ	1
Fish, P	1
McCabe, CH	9
Majure, DT	1
Aberegg, SK	1
McLaurin, BT	1
Cox, DA	1
Bertrand, ME	1
Pocock, SJ	1
Ware, JH	1
Aylward, PE	1
Cequier, AR	1
Darius, H	1
Desmet, W	1
Ebrahimi, R	1
Hamon, M	1
Rasmussen, LH	1
Rupprecht, HJ	1
Hoekstra, J	1
Oliveira, GB	1
Avezum, A	1
Anderson, FA	1
Dabbous, OH	1
Goldberg, RJ	1
Brieger, D	1
Gore, JM	1
Lee, S	1
Friedewald, VE	1
Roberts, WC	1
Eikelboom, JW	1
Faxon, DP	1
Barantke, M	1
Bonnemeier, H	1
Smith, RE	1
Townsend, GE	1
Berry, BR	1
Bowen, T	1
Demers, C	3
Fromell, GJ	5
Xiao, Z	1
Sacks, DB	1
Rifai, N	2
Cannon, CP	4
Noble, S	1
Spencer, CM	1
Philippe, F	2
Vicaut, E	2
Bearez, E	1
Poulard, JE	1
Carrie, D	1
Flammang, D	1
Dutoit, A	1
Carayon, A	1
Jardel, C	1
Chevrot, M	1
Bastard, JP	1
Gurfinkel, E	2
Scirica, BM	1
Mark, DB	1
Bernink, PJ	3
Salein, D	2
Bayes De Luna, A	2
Fox, K	1
Lablanche, JM	2
Purcell, H	1
Fox, KM	2
Weber, S	1
Laramée, P	1
Huynh, T	1
Diodati, JG	1
Squire, IB	1
Deckelbaum, LI	1
Thornton, AR	1
Harris, KE	1
Sax, FL	1
Lo, MW	1
Brener, SJ	1
Creekmore, F	1
Hilpert, U	1
Spencer, FA	2
Ball, SP	2
Zhang, Q	1
Liu, L	1
Benoit, S	1
Wang, JC	1
Goldhaber, SZ	1
Popma, JJ	1
Monrad, ES	1
Stinnett, SS	1
Weatherley, BD	1
Lison, L	3
Perlemuter, K	1
Horacek, T	1
Papuchis, G	1
Mautner, B	3
Radley, DR	2
Le Iouer, V	1
Detournay, B	1
Huet, X	1
Fagnani, F	1
Harvey, DM	1
Offord, RH	1
King, SB	1
Topol, EJ	1
Van de Werf, F	1
Willerson, JT	1
Barr, A	1
Sobtchouk, A	1
Laperrière, L	1
Hill, C	1
Tanasijevic, M	1
Shively, BK	1
Sotirov, I	1
Santopinto, J	1
Torres, V	1
Marcos, E	1
Holper, EM	1
Willan, AR	1
O'Brien, BJ	1
Salvioni, A	1
Casilli, F	1
Assanelli, E	1
Grazi, M	1
Marenzi, G	1
Guazzi, MD	1
Nicholson, T	1
McGuire, A	1
Milne, R	1
Berkowitz, SD	1
Stinnett, S	1
Diuguid, DL	1
Hödl, R	1
Kraxner, W	1
Nikfardjam, M	1
Schumacher, M	1
Fruhwald, FM	1
Zorn, G	1
Wonisch, M	1
Klein, W	3
Neudorfer, M	1
Leibovitch, I	1
Goldstein, M	1
Loewenstein, A	1
Gori, AM	1
Fedi, S	1
Pepe, G	1
Falciani, M	1
Rogolino, A	1
Prisco, D	1
Gensini, GF	1
Abbate, R	1
Gibson, M	1
Rush, JE	1
Sanderink, G	1
Sabatine, MS	1
Giugliano, RP	1
Preisack, MB	1
Bonan, R	1
Meisner, C	1
Eschenfelder, V	1
Karsch, KR	1
Möller, BH	1
Furman, MI	1
Kereiakes, DJ	1
Krueger, LA	1
Mueller, MN	1
Broderick, TM	1
Schneider, JF	1
Howard, WL	1
Fox, ML	1
Barnard, MR	1
Frelinger, AL	1
Michelson, AD	1
Hong, YJ	1
Jeong, MH	1
Lee, SH	1
Park, OY	1
Kim, JH	1
Kim, W	1
Rhew, JY	1
Ahn, YK	1
Cho, JG	1
Park, JC	1
Suh, SP	1
Ahn, BH	1
Kim, SH	1
Kang, JC	1
Diderholm, E	1
Andrén, B	1
Frostfeldt, G	1
Genberg, M	1
Jernberg, T	3
Lagerqvist, B	2
Lindahl, B	6
Manoharan, G	1
Adgey, AA	1
James, SK	2
Siegbahn, A	5
Armstrong, P	1
Barnathan, E	1
Califf, R	1
Simoons, ML	1
Janzon, M	1
Levin, LA	1
Swahn, E	4
Paparella, S	1
Lindbäck, J	2
Johnston, N	2
Stridsberg, M	1
Venge, P	1
Oldgren, J	1
Kirichenko, AA	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Effect of Low Molecular Weight Heparin vs Unfractionated Heparin on Bleeding After Cardiac Surgery[NCT00420667]		43 participants (Actual)	Interventional	2004-11-30	Completed
Optimizing the Anticoagulation Regimen of Enoxaparin During Percutaneous Coronary Intervention[NCT03145675]	Phase 4	378 participants (Actual)	Interventional	2017-05-12	Completed
Pharmacodynamics Study of Enoxalow, Produced by Blau Farmacêutica S/A, Compared to Clexane, Produced by Sanofi-Aventis Farmacêutica Ltda, in Healthy Subjects After Intravenous Administration.[NCT01692171]	Phase 1	32 participants (Actual)	Interventional	2013-02-28	Completed
Anti-Xa Assay Correlation to the Efficacy and Safety of Enoxaparin in the Treatment of Pulmonary Embolism[NCT02977013]		42 participants (Actual)	Observational	2013-08-31	Completed
Single Center Registry of Non-STEMI Acute Coronary Syndrome Patients Treated With Bivalirudin[NCT00842374]		32 participants (Actual)	Observational	2008-12-31	Completed
Impact of Residual Syntax Score and Syntax Revascularization Index on Outcomes of Acute Coronary Syndrome Patients With Multi-Vessel Disease[NCT03138473]		149 participants (Actual)	Observational	2018-07-01	Completed
An International Randomised Trial of Early Versus Delayed Invasive Strategies in Patients With Non-ST Segment Elevation Acute Coronary Syndromes[NCT00552513]		3,031 participants (Actual)	Interventional	2005-05-31	Completed
An International, Randomized, Double-blind Study Evaluating the Efficacy and Safety of Fondaparinux Versus Enoxaparin in the Acute Treatment of Unstable Angina/Non ST-segment Elevation MI Acute Coronary Syndromes[NCT00139815]	Phase 3	20,078 participants (Actual)	Interventional	2003-04-30	Completed
The ACUITY Trial: A Randomized Comparison of Angiomax (Bivalirudin) Versus Heparin (Unfractionated Heparin or Enoxaparin) in Patients Undergoing Early Invasive Management for Acute Coronary Syndromes Without ST-Segment Elevation[NCT00093158]	Phase 3	13,800 participants	Interventional	2003-08-31	Completed
Study of the Efficacy, Safety and Tolerability of Low Molecular Weight Heparin vs. Unfractionated Heparin as Bridging Therapy in Patients With Embolic Stroke Due to Atrial Fibrillation[NCT02159287]	Phase 2	80 participants (Anticipated)	Interventional	2014-01-31	Recruiting
A Double Blind Randomized Control Trial of Post-Operative Low Molecular Weight Heparin Bridging Therapy Versus Placebo Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism (PERIOP 2)[NCT00432796]	Phase 3	1,473 participants (Actual)	Interventional	2006-12-31	Active, not recruiting
Randomized Investigation of Chest Pain Diagnostic Strategies[NCT01035047]		105 participants (Actual)	Interventional	2010-01-31	Completed
Randomized Cost Comparison of Cardiac MRI Use in ED Patients With Chest Pain[NCT00678639]		110 participants (Actual)	Interventional	2008-01-31	Completed
Improving Early Risk Stratification in Patients Presenting to Emergency Departments With Undifferentiated Chest Pain[NCT02364271]		602 participants (Actual)	Observational	2013-03-31	Completed
A Randomized Cost Minimization Analysis Comparing Same Day Discharge With Overnight Hospital Stay Following Elective and Low Risk Urgent Percutaneous Coronary Intervention.[NCT02207270]		4 participants (Actual)	Interventional	2014-08-11	Terminated (stopped due to Unable to meet projected enrollment)
Serum Oxidative Status as a Potential Predictor of Coronary Artery Disease.[NCT03646019]		200 participants (Anticipated)	Observational	2018-09-30	Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Intervention	Eparticipants (Number)
Early Intervention	264
Delayed Intervention	280

Intervention	participants (Number)
Early Intervention	153
Delayed Intervention	163

Intervention	participants (Number)
Early Intervention	151
Delayed Intervention	186

Intervention	participants (Number)
CDU-CMR Protocol	0
Inpatient Care	3

(NCT01035047)
Timeframe: Duration of Index Hospitalization, an average of 1-2 days

Mortality

Stress Testing-related Adverse Event

The Composite of Revascularization, Re-hospitalization, and Recurrent Cardiac Testing Through 90 Days.

Adverse Events During Magnetic Resonance Imaging (MRI) Scanning

Intervention	hours (Median)
CDU-CMR Protocol	21.1
Inpatient Care	26.3

Intervention	participants (Number)
CDU-CMR Protocol	0
Inpatient Care	0

Intervention	participants (Number)
CDU-CMR Protocol	1
Inpatient Care	0

Intervention	participants (Number)
CDU-CMR Protocol	7
Inpatient Care	20

Any event leading to early termination of the MRI acquisition, or requiring intervention by a physician, will be considered an adverse event related to MRI, excluding physician termination of image acquisition due to concerns of cardiac ischemia. (NCT00678639)
Timeframe: Occuring in the MRI scanning suite or within 30 minutes of the last image acquisition.

Correct Admission Decision, Based Upon the Reference Standard of Acute Coronary Syndrome (ACS) at 30 Days

Intervention	Participants (Number)
Emergency Department (ED) Observation Unit	3
Usual Care	1

Participants with ACS and admitted or not experiencing ACS and discharged will be considered a correct admission decision. Remaining participants will be considered to have incorrect admission decisions. (NCT00678639)
Timeframe: 30 Days

Cost of Index Hospitalization

Intervention	Participants (Number)
Emergency Department (ED) Observation Unit	43
Usual Care	6

Index hospitalization refers to the hospital visit during which the participant was enrolled in the trial. The primary outcome is examining the cost for this visit. (NCT00678639)
Timeframe: Emergency Department (ED) arrival through hospital discharge, median length of stay was 28.1 hours

The Number of Participants Randomized to the OU and Were Able to Complete CMR Imaging

Intervention	US Dollars (Median)
Emergency Department (ED) Observation Unit	2062
Usual Care	2680

The number of participants able to complete the planned imaging sequences will be measured. (NCT00678639)
Timeframe: Emergency Department (ED) arrival through hospital discharge

Number of Participants Who Utilized the Indicated Health Care Procedures

Intervention	Participants (Number)
Emergency Department (ED) Observation Unit	46

Measured as self report, assessed during telephone follow-up. (NCT00678639)
Timeframe: 30d, 3mo, 6mo, and 1 year

Number of Effecacy MACE

Intervention	Participants (Number)
	Cardiac related office visit	Cardiac related ED visit	Cardiac related hospitalization	Cardiac related procedures	Cardiac Catheterization	Stress Test	Resting Echocardiogram
Emergency Department (ED) Observation Unit	7	0	0	0	0	0	0
Usual Care	4	4	3	4	3	1	1

Outcome is the number of patients with effecacy MACE within 30 days after initial ED presentation. Effecacy MACE consists of revascularization (e.g.coronary artery bypass grafting),ventricular arrhythmia needing intervention and high-degree atrioventricular block needing intervention. (NCT02364271)
Timeframe: 30 days

Number of Safety Major Adverse Cardiac Event

Intervention	Participants (Count of Participants)
Not Low Risk Group	26
Low Risk Group	0

Outcome is the number of patients with safety MACE within 30 days after initial ED presentation. Safety MACE is defined as relating to safety outcome,which consists of all-cause mortality (included cardiac death),cardiac arrest,readmission with myocardial infarction and cardiogenic shock (NCT02364271)
Timeframe: 30 Days

Article	Year
Low molecular weight heparins in the treatment of unstable angina. Minerva cardioangiologica, 2002, Volume: 50, Issue:6 Topics: Angina, Unstable; Clinical Trials as Topic; Dalteparin; Enoxaparin; Fibrinolytic Agents; Heparin, Lo	2002
[Heparin in the treatment of unstable angina. Can the decrease of the molecular size increase its effectiveness?]. Terapevticheskii arkhiv, 1998, Volume: 70, Issue:12 Topics: Angina, Unstable; Anticoagulants; Blood Coagulation Tests; Clinical Trials as Topic; Dalteparin; Eno	1998
Low-molecular-weight heparins in the management of acute coronary syndromes. Archives of internal medicine, 1999, Sep-13, Volume: 159, Issue:16 Topics: Angina, Unstable; Canada; Coronary Disease; Dalteparin; Enoxaparin; Fibrinolytic Agents; Hemorrhage;	1999
Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation, 1999, Oct-12, Volume: 100, Issue:15 Topics: Aged; Angina, Unstable; Anticoagulants; Dalteparin; Double-Blind Method; Electrocardiography; Enoxap	1999
Low molecular weight heparin in acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated heparin? Journal of the American College of Cardiology, 2000, Volume: 35, Issue:7 Topics: Acute Disease; Angina, Unstable; Anticoagulants; Clinical Trials as Topic; Dalteparin; Enoxaparin; H	2000
[Low molecular weight heparin in the treatment of acute coronary syndromes without ST-segment elevation: unstable angina and non-Q-wave myocardial infarction]. Medicina clinica, 2000, Nov-04, Volume: 115, Issue:15 Topics: Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as Topic; Confidence Intervals; Daltepari	2000
Therapy of unstable angina with the low molecular weight heparins. Vascular medicine (London, England), 2000, Volume: 5, Issue:4 Topics: Angina, Unstable; Anticoagulants; Dalteparin; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Inj	2000
[Low molecular weight heparins in acute coronary syndrome]. Herz, 2001, Volume: 26 Suppl 1 Topics: Acute Disease; Angina, Unstable; Anticoagulants; Controlled Clinical Trials as Topic; Dalteparin; En	2001
Glycoprotein IIb/IIIa antagonists and low-molecular weight heparin in acute coronary syndromes. Cardiology clinics, 2001, Volume: 19, Issue:2 Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Coronary Artery Bypass; Dalteparin; Enoxaparin;	2001
Anticoagulants in ischemia-guided management of non-ST-elevation acute coronary syndromes. The American journal of emergency medicine, 2017, Volume: 35, Issue:3 Topics: Acute Coronary Syndrome; American Heart Association; Angina, Unstable; Anticoagulants; Clinical Tria	2017
Pharmacologic plaque passivation for the reduction of recurrent cardiac events in acute coronary syndromes. Journal of the American College of Cardiology, 2003, Feb-19, Volume: 41, Issue:4 Suppl S Topics: Abciximab; Acute Disease; Angina, Unstable; Antibodies, Monoclonal; C-Reactive Protein; Coronary Art	2003
The role of low-molecular-weight heparin in the management of acute coronary syndromes. Journal of the American College of Cardiology, 2003, Feb-19, Volume: 41, Issue:4 Suppl S Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Blood Coagulation F	2003
Low-molecular-weight heparins: are they all the same? British journal of haematology, 2003, Volume: 121, Issue:1 Topics: Angina, Unstable; Blood Coagulation Tests; Dalteparin; Enoxaparin; Factor Xa Inhibitors; Heparin, Lo	2003
Costs and cost effectiveness of low molecular weight heparins and platelet glycoprotein IIb/IIIa inhibitors: in the management of acute coronary syndromes. PharmacoEconomics, 2003, Volume: 21, Issue:16 Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Coronary	2003
Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. JAMA, 2004, Jul-07, Volume: 292, Issue:1 Topics: Angina Pectoris; Angina, Unstable; Cause of Death; Enoxaparin; Fibrinolytic Agents; Hemorrhage; Hepa	2004
Clinical use of enoxaparin in the management of non-ST segment elevation acute coronary syndromes. Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:7 Topics: Acute Disease; Angina, Unstable; Anticoagulants; Coronary Disease; Enoxaparin; Heparin; Humans; Myoc	2005
Enoxaparin in acute coronary syndromes. Expert review of cardiovascular therapy, 2007, Volume: 5, Issue:3 Topics: Angina, Unstable; Anticoagulants; Clinical Trials as Topic; Enoxaparin; Humans; Myocardial Infarctio	2007
New anticoagulant options for ST-elevation myocardial infarction and unstable angina pectoris/non-ST-elevation myocardial infarction. Current cardiology reports, 2007, Volume: 9, Issue:4 Topics: Angina, Unstable; Anticoagulants; Electrocardiography; Enoxaparin; Fondaparinux; Heart Conduction Sy	2007
Factor Xa inactivation in acute coronary syndrome. Current pharmaceutical design, 2008, Volume: 14, Issue:12 Topics: Acute Coronary Syndrome; Angina, Unstable; Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Fondapa	2008
TIMI 11B. Enoxaparin versus unfractionated heparin for unstable angina or non-Q-wave myocardial infarction: a double-blind, placebo-controlled, parallel-group, multicenter trial. Rationale, study design, and methods. Thrombolysis in Myocardial Infarction American heart journal, 1998, Volume: 135, Issue:6 Pt 3 Su Topics: Angina, Unstable; Anticoagulants; Controlled Clinical Trials as Topic; Double-Blind Method; Enoxapar	1998
Enoxaparin. A review of its clinical potential in the management of coronary artery disease. Drugs, 1998, Volume: 56, Issue:2 Topics: Angina, Unstable; Angioplasty; Coronary Disease; Drug Tolerance; Enoxaparin; Fibrinolytic Agents; Hu	1998
Low molecular weight heparins in the cardiac catheterization laboratory. Journal of thrombosis and thrombolysis, 1999, Volume: 7, Issue:3 Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants;	1999
Optimising outcomes: socioeconomic perspective. Heart (British Cardiac Society), 1999, Volume: 82 Suppl 1 Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Cost Savings; Double-Blind Method;	1999
Anticoagulants in acute coronary syndromes. The American journal of cardiology, 1999, Sep-02, Volume: 84, Issue:5A Topics: Acute Disease; Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as Topic; Coronary Disease	1999
Implications of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) study and the results in the context of other trials. The American journal of cardiology, 1999, Sep-02, Volume: 84, Issue:5A Topics: Angina, Unstable; Anticoagulants; Clinical Trials as Topic; Dalteparin; Death, Sudden, Cardiac; Enox	1999
Unfractionated and low-molecular-weight heparins in acute coronary syndromes: current recommendations. Cleveland Clinic journal of medicine, 2000, Volume: 67, Issue:1 Topics: Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as Topic; Coronary Disease; Enoxaparin; F	2000
Low-molecular-weight heparin and platelet glycoprotein IIb/IIIa receptor blockade in the treatment of acute coronary syndromes: complementary or competing therapies? The Journal of invasive cardiology, 2000, Volume: 12 Suppl A Topics: Acetates; Angina, Unstable; Anticoagulants; Confidence Intervals; Controlled Clinical Trials as Topi	2000
Role of low-molecular-weight heparins in the management of patients with unstable angina pectoris and non-Q-wave acute myocardial infarction. The American journal of cardiology, 2000, Apr-27, Volume: 85, Issue:8A Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Heparin, Low-Molecular	2000
Low molecular weight heparin in acute coronary syndromes. Current cardiology reports, 1999, Volume: 1, Issue:3 Topics: Angina, Unstable; Angioplasty; Dalteparin; Enoxaparin; Fibrinolytic Agents; Heparin, Low-Molecular-W	1999
Low molecular weight heparins and coronary artery disease. Current cardiology reports, 2000, Volume: 2, Issue:1 Topics: Angina, Unstable; Anticoagulants; Coronary Disease; Enoxaparin; Heparin, Low-Molecular-Weight; Human	2000
Management of venous and cardiovascular thrombosis: enoxaparin. Hospital medicine (London, England : 1998), 2000, Volume: 61, Issue:9 Topics: Angina, Unstable; Anticoagulants; Coronary Thrombosis; Enoxaparin; Fibrinolytic Agents; Humans; Myoc	2000
Redefining medical treatment in the management of unstable angina. The American journal of medicine, 2000, Volume: 108, Issue:1 Topics: Abciximab; Administration, Oral; Angina, Unstable; Antibodies, Monoclonal; C-Reactive Protein; Diagn	2000
Deep venous thrombosis prophylaxis in patients with heart disease. Current cardiology reports, 2001, Volume: 3, Issue:1 Topics: Angina, Unstable; Anticoagulants; Critical Care; Enoxaparin; Heart Failure; Heparin; Humans; Myocard	2001
The role of low-molecular-weight heparins in the management of unstable angina and non-ST-segment elevation myocardial infarction. Journal of thrombosis and thrombolysis, 2001, Volume: 11, Issue:2 Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Cardiac Catheterization; Electroca	2001
Cost-utility of enoxaparin compared with unfractionated heparin in unstable coronary artery disease. BMC cardiovascular disorders, 2001, Volume: 1 Topics: Angina, Unstable; Anticoagulants; Cost-Benefit Analysis; Enoxaparin; Fibrinolytic Agents; Humans; My	2001
Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE. European heart journal, 2002, Volume: 23, Issue:4 Topics: Angina, Unstable; Enoxaparin; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Myocardial	2002
Enoxaparin in unstable angina/non-ST-segment elevation myocardial infarction: treatment benefits in prespecified subgroups. Journal of thrombosis and thrombolysis, 2001, Volume: 12, Issue:3 Topics: Adult; Aged; Angina, Unstable; Clinical Trials, Phase III as Topic; Electrocardiography; Enoxaparin;	2001
Current management of unstable angina: lessons from the TACTICS-TIMI 18 trial. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2002, Volume: 2, Issue:4 Topics: Angina, Unstable; Angioplasty, Balloon; Aspirin; Dalteparin; Drug Therapy, Combination; Fibrinolytic	2002
Thrombolytic therapy: no room for error. Journal of emergency nursing, 2004, Volume: 30, Issue:4 Topics: Angina, Unstable; Dalteparin; Emergency Nursing; Fatal Outcome; Fibrinolytic Agents; Humans; Male; M	2004
Biochemical markers of myocardial damage for early diagnosis and prognosis in patients with acute coronary syndromes. Minireview based on a doctorial thesis. Upsala journal of medical sciences, 1996, Volume: 101, Issue:3 Topics: Aged; Angina, Unstable; Anticoagulants; Biomarkers; Cohort Studies; Creatine Kinase; Dalteparin; End	1996
[Low molecular weight heparin in unstable angina]. Archives des maladies du coeur et des vaisseaux, 1996, Volume: 89, Issue:11 Suppl Topics: Angina, Unstable; Anticoagulants; Aspirin; Dalteparin; Dose-Response Relationship, Drug; Drug Therap	1996
Long-term management--the way forward? Clinical cardiology, 2000, Volume: 23 Suppl 1 Topics: Angina, Unstable; Anticoagulants; Aspirin; Coronary Artery Disease; Dalteparin; Drug Therapy, Combin	2000
Targeting treatment for optimal outcome. Clinical cardiology, 2000, Volume: 23 Suppl 1 Topics: Age Factors; Aged; Angina, Unstable; Anticoagulants; Aspirin; Biomarkers; Clinical Protocols; Daltep	2000
[Long-term administration of Dalteparin in unstable coronary syndrome. FRISC II study opens novel therapeutic perspectives. Fragmin and Fast Revascularization during Instability in Coronary Artery Disease]. Der Internist, 2000, Volume: 41, Issue:1 Topics: Angina, Unstable; Anticoagulants; Controlled Clinical Trials as Topic; Dalteparin; Death, Sudden, Ca	2000
Implications of the FRISCII trial: initial medical stabilization followed by an early invasive approach is the preferred strategy in unstable coronary syndromes. Scandinavian cardiovascular journal : SCJ, 2000, Volume: 34, Issue:1 Topics: Angina, Unstable; Dalteparin; Electrocardiography; Fibrinolytic Agents; Humans; Injections, Intraven	2000
Acute and prolonged treatment with low-molecular-weight heparin therapy in patients with unstable coronary artery disease. Annals of medicine, 2000, Volume: 32 Suppl 1 Topics: Angina, Unstable; Dalteparin; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Myocardial	2000
Low-molecular-weight heparin as a bridge to timely revascularization in unstable coronary artery disease -- an update of the Fragmin during Instability in Coronary Artery Disease II Trial. Haemostasis, 2000, Volume: 30 Suppl 2 Topics: Algorithms; Angina, Unstable; Anticoagulants; Biomarkers; Combined Modality Therapy; Coronary Angiog	2000

Article	Year
Tolerability of percutaneous coronary interventions in patients receiving nadroparin calcium for unstable angina or non-Q-wave myocardial infarction: the Angiofrax study. Current medical research and opinion, 2003, Volume: 19, Issue:2 Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Female; Fibrinolytic Agents; Hemorrhage; Hum	2003
Effects of enoxaparin and nadroparin on major cardiac events in high-risk unstable angina treated with a glycoprotein IIb/IIIa inhibitor. Japanese heart journal, 2003, Volume: 44, Issue:6 Topics: Aged; Angina, Unstable; Anticoagulants; Double-Blind Method; Drug Therapy, Combination; Enoxaparin;	2003
A randomized controlled clinical trial to evaluate the efficacy, safety, cost-effectiveness and effect on PAI-1 levels of the three low-molecular-weight heparins--enoxaparin, nadroparin and dalteparin. The ESCAPe-END study. Pharmacology, 2006, Volume: 78, Issue:3 Topics: Adult; Aged; Angina, Unstable; Cost-Benefit Analysis; Dalteparin; Disease-Free Survival; Drug Admini	2006
[Comparison of low-molecular-weight heparin and unfractionated heparin in the treatment of unstable angina]. Revista medica de Chile, 1998, Volume: 126, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Female; Heparin; Humans; Male; Mid	1998
Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation, 1999, Oct-12, Volume: 100, Issue:15 Topics: Aged; Angina, Unstable; Anticoagulants; Dalteparin; Double-Blind Method; Electrocardiography; Enoxap	1999
Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischa European heart journal, 1999, Volume: 20, Issue:21 Topics: Adult; Angina, Unstable; Anticoagulants; Double-Blind Method; Female; Humans; Male; Myocardial Infar	1999
5-year clinical outcomes in the ICTUS (Invasive versus Conservative Treatment in Unstable coronary Syndromes) trial a randomized comparison of an early invasive versus selective invasive management in patients with non-ST-segment elevation acute coronary Journal of the American College of Cardiology, 2010, Mar-02, Volume: 55, Issue:9 Topics: Abciximab; Acute Coronary Syndrome; Adolescent; Adult; Aged; Aged, 80 and over; Angina, Unstable; An	2010
Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris/non-ST-segment elevation acute myocardial infarction having subsequent percutaneous coronary intervention. The American journal of cardiology, 2002, Sep-01, Volume: 90, Issue:5 Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Combined Modality Therapy; Electro	2002
Comparison of two needle sizes for subcutaneous administration of enoxaparin: effects on size of hematomas and pain on injection. Pharmacotherapy, 2002, Volume: 22, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Enoxaparin; Female; Hematoma; Huma	2002
Head-to-head comparison of two different low-molecular-weight heparins in acute coronary syndrome: a single center experience. Japanese heart journal, 2002, Volume: 43, Issue:5 Topics: Aged; Angina, Unstable; Anticoagulants; Dalteparin; Enoxaparin; Female; Heparin, Low-Molecular-Weigh	2002
Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study). The American journal of cardiology, 2003, Apr-15, Volume: 91, Issue:8 Topics: Angina, Unstable; Anticoagulants; Biomarkers; Blood Platelets; Dalteparin; Enoxaparin; Female; Hepar	2003
Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: the EVET trial. American heart journal, 2003, Volume: 146, Issue:2 Topics: Aged; Angina, Unstable; Enoxaparin; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Huma	2003
The impact on coagulation of an intravenous loading dose in addition to a subcutaneous regimen of low-molecular-weight heparin in the initial treatment of acute coronary syndromes. Journal of the American College of Cardiology, 2003, Aug-06, Volume: 42, Issue:3 Topics: Aged; Angina, Unstable; Anticoagulants; Blood Coagulation; Enoxaparin; Factor Xa; Female; Humans; In	2003
Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non-ST-segment elevation myocardial infarction. British journal of clinical pharmacology, 2003, Volume: 56, Issue:4 Topics: Angina, Unstable; Anticoagulants; Cohort Studies; Enoxaparin; Factor Xa Inhibitors; Female; Half-Lif	2003
Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. American heart journal, 2003, Volume: 146, Issue:4 Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants;	2003
Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation, 2004, Jul-27, Volume: 110, Issue:4 Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Cardiac Catheter	2004
Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation, 2004, Jul-27, Volume: 110, Issue:4 Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Cardiac Catheter	2004
Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation, 2004, Jul-27, Volume: 110, Issue:4 Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Cardiac Catheter	2004
Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation, 2004, Jul-27, Volume: 110, Issue:4 Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Cardiac Catheter	2004
Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library. American heart journal, 2004, Volume: 148, Issue:2 Topics: Angina, Unstable; Anticoagulants; Coronary Angiography; Electrocardiography; Enoxaparin; Heparin; Hu	2004
Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. American heart journal, 2004, Volume: 148, Issue:5 Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Antithrombins; Cardiac Catheteriza	2004
Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. American heart journal, 2004, Volume: 148, Issue:5 Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Antithrombins; Cardiac Catheteriza	2004
Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. American heart journal, 2004, Volume: 148, Issue:5 Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Antithrombins; Cardiac Catheteriza	2004
Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. American heart journal, 2004, Volume: 148, Issue:5 Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Antithrombins; Cardiac Catheteriza	2004
Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: results of the enoxaparin versus tinzaparin (EVET) trial at 6 months. American heart journal, 2005, Volume: 150, Issue:3 Topics: Acute Disease; Aged; Angina, Unstable; Electrocardiography; Enoxaparin; Female; Follow-Up Studies; H	2005
Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes. American heart journal, 2005, Volume: 150, Issue:6 Topics: Acute Disease; Aged; Angina, Unstable; Anticoagulants; Coronary Disease; Double-Blind Method; Enoxap	2005
Using a clinical pathway and education to reduce inappropriate prescribing of enoxaparin in patients with acute coronary syndromes: a controlled study. Internal medicine journal, 2006, Volume: 36, Issue:1 Topics: Angina, Unstable; Anticoagulants; Critical Pathways; Drug Utilization; Enoxaparin; Female; Hospitals	2006
Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin American heart journal, 2006, Volume: 151, Issue:2 Topics: Angina, Unstable; Anticoagulants; Aspirin; Enoxaparin; Eptifibatide; Female; Heparin; Humans; Male;	2006
Comparison of fondaparinux and enoxaparin in acute coronary syndromes. The New England journal of medicine, 2006, Apr-06, Volume: 354, Issue:14 Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Female; Fondapar	2006
A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial. Journal of the American College of Cardiology, 2006, Jun-20, Volume: 47, Issue:12 Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Antithrombins; Drug Therapy, Combin	2006
Bivalirudin for patients with acute coronary syndromes. The New England journal of medicine, 2006, Nov-23, Volume: 355, Issue:21 Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Co	2006
Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. Journal of the American College of Cardiology, 2007, Oct-30, Volume: 50, Issue:18 Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Cohort Studies; Double-Blind Metho	2007
Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. Journal of the American College of Cardiology, 1997, Volume: 29, Issue:7 Topics: Aged; Angina, Unstable; Anticoagulants; Enoxaparin; Female; Hemorrhage; Humans; Male; Middle Aged; M	1997
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. The New England journal of medicine, 1997, Aug-14, Volume: 337, Issue:7 Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female;	1997
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. The New England journal of medicine, 1997, Aug-14, Volume: 337, Issue:7 Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female;	1997
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. The New England journal of medicine, 1997, Aug-14, Volume: 337, Issue:7 Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female;	1997
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. The New England journal of medicine, 1997, Aug-14, Volume: 337, Issue:7 Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female;	1997
Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation, 1998, Jan-27, Volume: 97, Issue:3 Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Antithrombi	1998
Time to positivity of a rapid bedside assay for cardiac-specific troponin T predicts prognosis in acute coronary syndromes: a Thrombolysis in Myocardial Infarction (TIMI) 11A substudy. Journal of the American College of Cardiology, 1998, Volume: 31, Issue:2 Topics: Aged; Angina, Unstable; Biomarkers; Cause of Death; Enoxaparin; Female; Fibrinolytic Agents; Follow-	1998
Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial. Circulation, 1998, Jul-28, Volume: 98, Issue:4 Topics: Aged; Angina, Unstable; Anticoagulants; C-Reactive Protein; Enoxaparin; Female; Fibrinogen; Heparin;	1998
ESSENCE trial results: breaking new ground. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events. The Canadian journal of cardiology, 1998, Volume: 14 Suppl E Topics: Adult; Angina, Unstable; Double-Blind Method; Enoxaparin; Female; Fibrinolytic Agents; Heparin, Low-	1998
Management of acute coronary syndromes with low molecular weight heparin: TIMI 11A and 11B. The Canadian journal of cardiology, 1998, Volume: 14 Suppl E Topics: Acute Disease; Angina, Unstable; Coronary Disease; Enoxaparin; Female; Fibrinolytic Agents; Heparin,	1998
Low molecular weight heparin (enoxaparin) in the management of unstable angina: the ESSENCE study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events. Heart (British Cardiac Society), 1999, Volume: 82 Suppl 1 Topics: Adult; Aged; Angina, Unstable; Anticoagulants; Disease-Free Survival; Double-Blind Method; Enoxapari	1999
Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation, 1999, Oct-12, Volume: 100, Issue:15 Topics: Acute Disease; Aged; Angina, Unstable; Anticoagulants; Creatine Kinase; Double-Blind Method; Electro	1999
Combination therapy with tirofiban and enoxaparin in acute coronary syndromes. International journal of cardiology, 1999, Dec-01, Volume: 71, Issue:3 Topics: Angina, Unstable; Coronary Angiography; Double-Blind Method; Drug Therapy, Combination; Electrocardi	1999
Predictors of recurrent ischemic events and death in unstable coronary artery disease after treatment with combination antithrombotic therapy. American heart journal, 2000, Volume: 139, Issue:6 Topics: Aged; Angina, Unstable; Aspirin; Drug Administration Routes; Drug Therapy, Combination; Electrocardi	2000
Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. Journal of the American College of Cardiology, 2000, Volume: 36, Issue:1 Topics: Aged; Angina, Unstable; Anticoagulants; Antithrombins; Aspirin; Biomarkers; Blood Platelets; Daltepa	2000
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA, 2000, Aug-16, Volume: 284, Issue:7 Topics: Aged; Angina, Unstable; Decision Making; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hepar	2000
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA, 2000, Aug-16, Volume: 284, Issue:7 Topics: Aged; Angina, Unstable; Decision Making; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hepar	2000
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA, 2000, Aug-16, Volume: 284, Issue:7 Topics: Aged; Angina, Unstable; Decision Making; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hepar	2000
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA, 2000, Aug-16, Volume: 284, Issue:7 Topics: Aged; Angina, Unstable; Decision Making; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hepar	2000
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA, 2000, Aug-16, Volume: 284, Issue:7 Topics: Aged; Angina, Unstable; Decision Making; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hepar	2000
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA, 2000, Aug-16, Volume: 284, Issue:7 Topics: Aged; Angina, Unstable; Decision Making; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hepar	2000
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA, 2000, Aug-16, Volume: 284, Issue:7 Topics: Aged; Angina, Unstable; Decision Making; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hepar	2000
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA, 2000, Aug-16, Volume: 284, Issue:7 Topics: Aged; Angina, Unstable; Decision Making; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hepar	2000
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA, 2000, Aug-16, Volume: 284, Issue:7 Topics: Aged; Angina, Unstable; Decision Making; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hepar	2000
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA, 2000, Aug-16, Volume: 284, Issue:7 Topics: Aged; Angina, Unstable; Decision Making; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hepar	2000
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA, 2000, Aug-16, Volume: 284, Issue:7 Topics: Aged; Angina, Unstable; Decision Making; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hepar	2000
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA, 2000, Aug-16, Volume: 284, Issue:7 Topics: Aged; Angina, Unstable; Decision Making; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hepar	2000
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA, 2000, Aug-16, Volume: 284, Issue:7 Topics: Aged; Angina, Unstable; Decision Making; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hepar	2000
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA, 2000, Aug-16, Volume: 284, Issue:7 Topics: Aged; Angina, Unstable; Decision Making; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hepar	2000
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA, 2000, Aug-16, Volume: 284, Issue:7 Topics: Aged; Angina, Unstable; Decision Making; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hepar	2000
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA, 2000, Aug-16, Volume: 284, Issue:7 Topics: Aged; Angina, Unstable; Decision Making; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hepar	2000
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA, 2000, Aug-16, Volume: 284, Issue:7 Topics: Aged; Angina, Unstable; Decision Making; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hepar	2000
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA, 2000, Aug-16, Volume: 284, Issue:7 Topics: Aged; Angina, Unstable; Decision Making; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hepar	2000
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA, 2000, Aug-16, Volume: 284, Issue:7 Topics: Aged; Angina, Unstable; Decision Making; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hepar	2000
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA, 2000, Aug-16, Volume: 284, Issue:7 Topics: Aged; Angina, Unstable; Decision Making; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hepar	2000
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA, 2000, Aug-16, Volume: 284, Issue:7 Topics: Aged; Angina, Unstable; Decision Making; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hepar	2000
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA, 2000, Aug-16, Volume: 284, Issue:7 Topics: Aged; Angina, Unstable; Decision Making; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hepar	2000
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA, 2000, Aug-16, Volume: 284, Issue:7 Topics: Aged; Angina, Unstable; Decision Making; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hepar	2000
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA, 2000, Aug-16, Volume: 284, Issue:7 Topics: Aged; Angina, Unstable; Decision Making; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hepar	2000
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA, 2000, Aug-16, Volume: 284, Issue:7 Topics: Aged; Angina, Unstable; Decision Making; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hepar	2000
Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events. Journal of the American College of Cardiology, 2000, Volume: 36, Issue:3 Topics: Adult; Aged; Angina, Unstable; Cardiac Catheterization; Double-Blind Method; Enoxaparin; Female; Fib	2000
Economic evaluation of enoxaparin sodium versus heparin in unstable angina. A French sub-study of the ESSENCE trial. PharmacoEconomics, 2000, Volume: 18, Issue:1 Topics: Angina, Unstable; Anticoagulants; Cost-Benefit Analysis; Enoxaparin; France; Heparin; Humans	2000
Superiority of enoxaparin versus unfractionated heparin for unstable angina/non-Q-wave myocardial infarction regardless of activated partial thromboplastin time. American heart journal, 2000, Volume: 140, Issue:4 Topics: Aged; Angina, Unstable; Double-Blind Method; Electrocardiography; Enoxaparin; Fibrinolytic Agents; H	2000
Low molecular weight heparin decreases rebound ischemia in unstable angina or non-Q-wave myocardial infarction: the Canadian ESSENCE ST segment monitoring substudy. Journal of the American College of Cardiology, 2000, Nov-01, Volume: 36, Issue:5 Topics: Aged; Angina, Unstable; Electrocardiography; Enoxaparin; Female; Fibrinolytic Agents; Follow-Up Stud	2000
Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes. The Journal of invasive cardiology, 2000, Volume: 12 Suppl E Topics: Angina, Unstable; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Enoxaparin; F	2000
Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation, 2001, Feb-06, Volume: 103, Issue:5 Topics: Aged; Angina, Unstable; Angioplasty; Catheterization; Enoxaparin; Female; Fibrinolytic Agents; Follo	2001
Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin. American heart journal, 2001, Volume: 141, Issue:4 Topics: Angina, Unstable; Anticoagulants; Aspirin; Double-Blind Method; Enoxaparin; Female; Heparin; Humans;	2001
Enoxaparin in unstable angina patients with renal failure. International journal of cardiology, 2001, Volume: 80, Issue:1 Topics: Aged; Angina, Unstable; Anticoagulants; Enoxaparin; Female; Humans; Male; Renal Insufficiency	2001
Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation. Thrombosis and haemostasis, 2001, Volume: 86, Issue:4 Topics: Acute Disease; Aged; Angina, Unstable; Anticoagulants; Antithrombin III; Biomarkers; Cardiovascular	2001
Prospective comparison of hemorrhagic complications after treatment with enoxaparin versus unfractionated heparin for unstable angina pectoris or non-ST-segment elevation acute myocardial infarction. The American journal of cardiology, 2001, Dec-01, Volume: 88, Issue:11 Topics: Aged; Angina, Unstable; Antifibrinolytic Agents; Double-Blind Method; Electrocardiography; Enoxapari	2001
The SYNERGY trial: study design and rationale. American heart journal, 2002, Volume: 143, Issue:6 Topics: Acute Disease; Adult; Aged; Angina, Unstable; Anticoagulants; Coronary Disease; Enoxaparin; Fibrinol	2002
Identification of patients at high risk for death and cardiac ischemic events after hospital discharge. American heart journal, 2002, Volume: 143, Issue:6 Topics: Angina, Unstable; Anticoagulants; Enoxaparin; Fibrinolytic Agents; Heparin; Humans; Myocardial Infar	2002
Incidence, outcome and prediction of early clinical events following percutaneous transluminal coronary angioplasty. A comparison between treatment with reviparin and unfractionated heparin/placebo (results of a substudy of the REDUCE trial). European heart journal, 1998, Volume: 19, Issue:8 Topics: Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Female; Heparin;	1998
Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention. American heart journal, 2003, Volume: 145, Issue:2 Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants;	2003
Effects of an early invasive strategy on ischemia and exercise tolerance among patients with unstable coronary artery disease. The American journal of medicine, 2003, Dec-01, Volume: 115, Issue:8 Topics: Angina, Unstable; Coronary Angiography; Dalteparin; Exercise Test; Exercise Tolerance; Female; Fibri	2003
Activation of the inflammation, coagulation, and fibrinolysis systems, without influence of abciximab infusion in patients with non-ST-elevation acute coronary syndromes treated with dalteparin: a GUSTO IV substudy. American heart journal, 2004, Volume: 147, Issue:2 Topics: Abciximab; Aged; Angina, Unstable; Antibodies, Monoclonal; Anticoagulants; Biomarkers; Blood Coagula	2004
Invasive treatment in unstable coronary artery disease promotes health-related quality of life: results from the FRISC II trial. American heart journal, 2004, Volume: 148, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Da	2004
Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a Fragmin and fast Revascularisation during In Stability in Coronary artery disease (FRISC)-II substudy. Journal of the American College of Cardiology, 2005, Feb-15, Volume: 45, Issue:4 Topics: Acute Disease; Aged; Angina, Unstable; Dalteparin; Electrocardiography; Female; Fibrinolytic Agents;	2005
Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Lancet (London, England), 1996, Mar-02, Volume: 347, Issue:9001 Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Aspirin; Coronary Disease; Daltepa	1996
Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC) Circulation, 1997, Jul-01, Volume: 96, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Aspirin; Blood Coagulation Tests;	1997
Low-molecular-weight heparin (Fragmin) during instability in coronary artery disease (FRISC). FRISC Study Group. The American journal of cardiology, 1997, Sep-04, Volume: 80, Issue:5A Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Aspirin; Dalteparin; Double-Blind	1997
Fragmin in unstable angina pectoris or in non-Q-wave acute myocardial infarction (the FRIC study). Fragmin in Unstable Coronary Artery Disease. The American journal of cardiology, 1997, Sep-04, Volume: 80, Issue:5A Topics: Angina, Unstable; Anticoagulants; Dalteparin; Humans; Injections, Subcutaneous; Myocardial Infarctio	1997
Long-term low-molecular-weight heparin (Fragmin) and/or early revascularization during instability in coronary artery disease (the FRISC II Study). The American journal of cardiology, 1997, Sep-04, Volume: 80, Issue:5A Topics: Angina, Unstable; Anticoagulants; Coronary Angiography; Coronary Disease; Dalteparin; Drug Therapy,	1997
Low-molecular weight heparin reduces the generation and activity of thrombin in unstable coronary artery disease. Thrombosis and haemostasis, 1998, Volume: 79, Issue:3 Topics: Aged; Angina, Unstable; Dalteparin; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardi	1998
Influences of sex and smoking habits on anticoagulant activity in low-molecular-weight heparin treatment of unstable coronary artery disease. American heart journal, 1999, Volume: 137, Issue:1 Topics: Adult; Angina, Unstable; Anticoagulants; Blood Coagulation; Coronary Disease; Dalteparin; Drug Admin	1999
Contemporary approach to management of unstable angina. Lancet (London, England), 1999, Aug-28, Volume: 354, Issue:9180 Topics: Aged; Angina, Unstable; Dalteparin; Double-Blind Method; Female; Humans; Male; Middle Aged; Myocardi	1999
Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease. Investigators. Lancet (London, England), 1999, Aug-28, Volume: 354, Issue:9180 Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Cohort Studies; Dalteparin; Double-Blind Method; F	1999
Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet (London, England), 1999, Aug-28, Volume: 354, Issue:9180 Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Dalteparin; Female; Humans; Long-Term Care; Male;	1999
Long-term management--the way forward? Clinical cardiology, 2000, Volume: 23 Suppl 1 Topics: Angina, Unstable; Anticoagulants; Aspirin; Coronary Artery Disease; Dalteparin; Drug Therapy, Combin	2000
Effect of low molecular weight heparin (fragmin) on bleeding after cardiac surgery. The Annals of thoracic surgery, 2000, Volume: 69, Issue:3 Topics: Aged; Angina, Unstable; Anticoagulants; Dalteparin; Female; Humans; Male; Middle Aged; Postoperative	2000
Acute and prolonged treatment with low-molecular-weight heparin therapy in patients with unstable coronary artery disease. Annals of medicine, 2000, Volume: 32 Suppl 1 Topics: Angina, Unstable; Dalteparin; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Myocardial	2000
Low-molecular-weight heparin as a bridge to timely revascularization in unstable coronary artery disease -- an update of the Fragmin during Instability in Coronary Artery Disease II Trial. Haemostasis, 2000, Volume: 30 Suppl 2 Topics: Algorithms; Angina, Unstable; Anticoagulants; Biomarkers; Combined Modality Therapy; Coronary Angiog	2000
Improving outcomes in acute coronary syndromes--the FRISC II trial. Clinical cardiology, 2001, Volume: 24, Issue:3 Suppl Topics: Adult; Angina, Unstable; Anticoagulants; Dalteparin; Female; Humans; Male; Myocardial Infarction; My	2001
Is early invasive treatment of unstable coronary artery disease equally effective for both women and men? FRISC II Study Group Investigators. Journal of the American College of Cardiology, 2001, Volume: 38, Issue:1 Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Coronary Artery Bypass; Dalteparin; Female;	2001
Rebound thrombin generation after heparin therapy in unstable angina. A randomized comparison between unfractionated and low-molecular-weight heparin. Journal of the American College of Cardiology, 2002, Mar-06, Volume: 39, Issue:5 Topics: Angina, Unstable; Anticoagulants; Coronary Thrombosis; Dalteparin; Female; Fibrinolysis; Heparin; He	2002
Continuous multilead ST-monitoring identifies patients with unstable coronary artery disease who benefit from extended antithrombotic treatment. European heart journal, 2002, Volume: 23, Issue:14 Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Coronary Disease; Dalteparin; Dose-Response Relati	2002

Article	Year
[The effect of fraxiparin on thrombocytic-vascular hemostasis in patients with unstable stenocardia]. Terapevticheskii arkhiv, 1993, Volume: 65, Issue:8 Topics: Adult; Aged; Angina, Unstable; Blood Platelets; Blood Vessels; Chronic Disease; Drug Evaluation; Dru	1993
Low-molecular weight heparins. The Journal of the Arkansas Medical Society, 1997, Volume: 93, Issue:11 Topics: Angina, Unstable; Animals; Anticoagulants; Antithrombins; Clinical Trials as Topic; Dalteparin; Enox	1997
[Risk stratification in acute coronary syndrome]. Herz, 2001, Volume: 26 Suppl 1 Topics: Abciximab; Acute Disease; Angina, Unstable; Antibodies, Monoclonal; Anticoagulants; Biomarkers; Clin	2001
Non-therapeutic anti-Xa levels in medical patients receiving anticoagulant therapy with enoxaparin. Thrombosis research, 2013, Volume: 132, Issue:4 Topics: Aged; Angina, Unstable; Anticoagulants; Cohort Studies; Drug Monitoring; Enoxaparin; Factor Xa; Fact	2013
2007 Guideline update for unstable angina/non-ST-segment elevation myocardial infarction: focus on antiplatelet and anticoagulant therapies. The Annals of pharmacotherapy, 2008, Volume: 42, Issue:7 Topics: American Heart Association; Angina, Unstable; Anticoagulants; Clopidogrel; Drug-Eluting Stents; Enox	2008
[Efficacy and safety of enoxaparin use during drug-eluting stents implantation]. Kardiologiia, 2008, Volume: 48, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Blood Vessel Prosthesis Implantation; Coated Mater	2008
Weight-based dosing of enoxaparin in obese patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE initiative. Pharmacotherapy, 2009, Volume: 29, Issue:6 Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Anticoagulants; Body Weight; Cohort Studies; Enoxap	2009
Preoperative use of enoxaparin compared with unfractionated heparin increases the incidence of re-exploration for postoperative bleeding after open-heart surgery in patients who present with an acute coronary syndrome: clinical investigation and reports. Circulation, 2002, Sep-24, Volume: 106, Issue:12 Suppl 1 Topics: Acute Disease; Aged; Angina, Unstable; Blood Component Transfusion; Coronary Artery Bypass; Coronary	2002
Pharmacokinetics of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2002, Volume: 57, Issue:2 Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Angiography; Enoxap	2002
Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials. Journal of the American College of Cardiology, 2003, Jan-01, Volume: 41, Issue:1 Topics: Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Aspirin; Creatinine; Drug Monitoring; Eno	2003
Inhibition of factor VIIa generation and prothrombin activation by treatment with enoxaparin in patients with unstable angina. British journal of haematology, 2003, Volume: 120, Issue:4 Topics: Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Enoxaparin; Factor VIIa; Factor Xa Inhibi	2003
The use of putative placebo in active control trials: two applications in a regulatory setting. Statistics in medicine, 2003, Mar-30, Volume: 22, Issue:6 Topics: Angina, Unstable; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase III as	2003
Rectus sheath haematoma with severe haemodynamic compromise after enoxaparin use for unstable angina. Resuscitation, 2003, Volume: 57, Issue:1 Topics: Angina, Unstable; Electrocardiography; Enoxaparin; Female; Follow-Up Studies; Hematoma; Hemodynamics	2003
[The safety and efficacy of pre-treatment with enoxaparin (Clexane) in acute coronary syndrome patients undergoing percutaneous coronary intervention]. Zhonghua nei ke za zhi, 2003, Volume: 42, Issue:2 Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Combined Modality Therapy; E	2003
Subcutaneous enoxaparin with early invasive strategy in patients with acute coronary syndromes. American heart journal, 2004, Volume: 147, Issue:4 Topics: Analysis of Variance; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Cardiac Cath	2004
Dosing practices and risk factors for bleeding in patients receiving enoxaparin for the treatment of an acute coronary syndrome. Chest, 2004, Volume: 125, Issue:5 Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Coronary Disease; E	2004
[Enoxaparin for the Treatment of Unstable Angina and Non-ST Segment Elevation Myocardial Infarction: the ENO-INT Study]. Kardiologiia, 2004, Volume: 44, Issue:6 Topics: Angina, Unstable; Anticoagulants; Enoxaparin; Heparin; Humans; Myocardial Infarction	2004
Fractionating heparins and their clinical trial data--something for everyone. JAMA, 2004, Jul-07, Volume: 292, Issue:1 Topics: Angina Pectoris; Angina, Unstable; Enoxaparin; Fibrinolytic Agents; Heparin; Humans; Myocardial Infa	2004
Fatal retroperitoneal haemorrhage associated with enoxaparin and impaired renal function. International journal of cardiology, 2005, Feb-28, Volume: 98, Issue:3 Topics: Aged; Angina, Unstable; Anticoagulants; Creatinine; Enoxaparin; Female; Hemorrhage; Humans; Kidney T	2005
Low-molecular-weight heparin-associated fat necrosis of the breast. Age and ageing, 2005, Volume: 34, Issue:2 Topics: Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Breast Diseases; Enoxaparin; Fat Necrosis	2005
Enoxaparin and percutaneous coronary intervention: a Canadian perspective. The Canadian journal of cardiology, 2005, May-01, Volume: 21, Issue:6 Topics: Angina, Unstable; Angioplasty, Balloon; Anticoagulants; Attitude of Health Personnel; Canada; Dose-R	2005
Dose capping enoxaparin is unjustified and denies patients with acute coronary syndromes a potentially effective treatment. Chest, 2005, Volume: 127, Issue:6 Topics: Acute Disease; Angina, Unstable; Anticoagulants; Biological Availability; Clinical Trials as Topic;	2005
Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome. Clinical pharmacology and therapeutics, 2005, Volume: 77, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Dose-Response Relationship, Drug; Enoxaparin; Fact	2005
Two cases of heparin induced thrombocytopenia type II post cardiopulmonary bypass. Anaesthesia and intensive care, 2006, Volume: 34, Issue:1 Topics: Aged; Angina, Unstable; Cardiopulmonary Bypass; Enoxaparin; Female; Follow-Up Studies; Humans; Male;	2006
Therapy for patients with acute coronary syndromes--new opportunities. The New England journal of medicine, 2006, Apr-06, Volume: 354, Issue:14 Topics: Angina, Unstable; Anticoagulants; Dose-Response Relationship, Drug; Enoxaparin; Fondaparinux; Hemorr	2006
The greatest benefit of enoxaparin over unfractionated heparin in acute coronary syndromes is achieved in patients presenting with ST-segment changes: the Enoxaparin in Non-Q-Wave Coronary Events (ESSENCE) Electrocardiogram Core Laboratory Substudy. American heart journal, 2006, Volume: 151, Issue:4 Topics: Angina, Unstable; Electrocardiography; Enoxaparin; Female; Fibrinolytic Agents; Heparin; Humans; Mal	2006
Fondaparinux versus enoxaparin in acute coronary syndromes. The New England journal of medicine, 2006, Jun-29, Volume: 354, Issue:26 Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Artery Bypass; Drug Thera	2006
Use of proven therapies in non-ST-elevation acute coronary syndromes according to evidence-based risk stratification. American heart journal, 2007, Volume: 153, Issue:4 Topics: Acute Disease; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Cardiac Catheterization; Enox	2007
The Editor's Roundtable: arterial thrombosis and acute coronary syndromes. The American journal of cardiology, 2007, Sep-15, Volume: 100, Issue:6 Topics: Administration, Cutaneous; Angina, Unstable; Anticoagulants; Cardiac Catheterization; Comorbidity; C	2007
Enoxaparin for unstable angina and ancrod for cardiac surgery following heparin allergy. The Annals of pharmacotherapy, 1996, Volume: 30, Issue:5 Topics: Aged; Ancrod; Angina, Unstable; Animals; Anticoagulants; Cattle; Coronary Artery Bypass; Diphenhydra	1996
Heparin in acute coronary disease--requiem for a heavyweight? The New England journal of medicine, 1997, Aug-14, Volume: 337, Issue:7 Topics: Angina, Unstable; Enoxaparin; Fibrinolytic Agents; Heparin; Humans; Myocardial Infarction	1997
Low molecular weight heparins (enoxaparin) in the management of unstable angina: the TIMI studies. Thrombolysis in Myocardial Infarction. Heart (British Cardiac Society), 1999, Volume: 82 Suppl 1 Topics: Angina, Unstable; Anticoagulants; Clinical Trials as Topic; Enoxaparin; Fibrinolytic Agents; Humans	1999
Pursuing progress in acute coronary syndromes. Circulation, 1999, Oct-12, Volume: 100, Issue:15 Topics: Acute Disease; Angina, Unstable; Anticoagulants; Clinical Trials as Topic; Coronary Disease; Enoxapa	1999
Improving outcome in acute coronary syndromes - as good as it gets? European heart journal, 1999, Volume: 20, Issue:21 Topics: Angina, Unstable; Anticoagulants; Dalteparin; Enoxaparin; Humans; Myocardial Infarction; Platelet Gl	1999
Enoxaparin and dalteparin in unstable angina: new indication. Enoxaparin: a reference treatment. Dalteparin: no better than unfractionated heparin. Prescrire international, 1999, Volume: 8, Issue:41 Topics: Angina, Unstable; Anticoagulants; Aspirin; Dalteparin; Enoxaparin; Humans; Myocardial Infarction; Tr	1999
Low molecular weight heparins in acute coronary syndrome. South Dakota journal of medicine, 2000, Volume: 53, Issue:1 Topics: Acute Disease; Angina, Unstable; Anticoagulants; Aspirin; Dalteparin; Double-Blind Method; Enoxapari	2000
Care for life. Central is the patient. Der Internist, 2000, Volume: 41, Issue:1 Topics: Angina, Unstable; Anticoagulants; Awards and Prizes; Death, Sudden, Cardiac; Enoxaparin; Germany; Hu	2000
Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by factor-Xa neutralization. Journal of thrombosis and thrombolysis, 2000, Volume: 9, Issue:3 Topics: Angina, Unstable; Blood Platelets; Enoxaparin; Factor Xa; Heparin, Low-Molecular-Weight; Humans; Myo	2000
Use of enoxaparin in a patient with unstable angina. The Journal of invasive cardiology, 2000, Volume: 12 Suppl C Topics: Angina, Unstable; Blood Chemical Analysis; Cardiac Catheterization; Coronary Angiography; Coronary A	2000
Antiplatelet drugs in cardiovascular prevention: coronary events: acute phase and secondary prevention. Prescrire international, 2000, Volume: 9, Issue:47 Topics: Angina, Unstable; Angioplasty; Anticoagulants; Aspirin; Cardiovascular Diseases; Clinical Trials as	2000
Management of unstable angina and myocardial infarction. Lancet (London, England), 2000, Sep-30, Volume: 356, Issue:9236 Topics: Angina, Unstable; Enoxaparin; Fibrinolytic Agents; Heparin; Heparin, Low-Molecular-Weight; Humans; M	2000
Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy. Journal of the American College of Cardiology, 2000, Nov-15, Volume: 36, Issue:6 Topics: Aged; Angina, Unstable; Enoxaparin; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Prognosi	2000
A simple, readily available method for risk stratification of patients with unstable angina and non-ST elevation myocardial infarction. The American journal of cardiology, 2001, Apr-15, Volume: 87, Issue:8 Topics: Aged; Angina, Unstable; Anticoagulants; Chi-Square Distribution; Enoxaparin; Female; Heparin; Humans	2001
Cost prediction models for the comparison of two groups. Health economics, 2001, Volume: 10, Issue:4 Topics: Angina, Unstable; Anticoagulants; Cost-Benefit Analysis; Drug Costs; Enoxaparin; Hospital Costs; Hum	2001
Choosing a parenteral anticoagulant agent. The New England journal of medicine, 2001, Nov-01, Volume: 345, Issue:18 Topics: Angina, Unstable; Anticoagulants; Enoxaparin; Fibrinolytic Agents; Fondaparinux; Heparin, Low-Molecu	2001
Moving beyond unfractionated heparin for acute coronary syndromes: Xeno's Paradox revisited. European heart journal, 2002, Volume: 23, Issue:4 Topics: Angina, Unstable; Clinical Protocols; Enoxaparin; Fibrinolytic Agents; Heparin; Humans	2002
Comparison of effects of dalteparin and enoxaparin on hemostatic parameters and von Willebrand factor in patients with unstable angina pectoris or non--ST- segment elevation acute myocardial infarction. The American journal of cardiology, 2002, Mar-01, Volume: 89, Issue:5 Topics: Aged; Angina, Unstable; Dalteparin; Dose-Response Relationship, Drug; Drug Administration Schedule;	2002
Massive choroidal hemorrhage associated with low molecular weight heparin therapy. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2002, Volume: 13, Issue:3 Topics: Acetazolamide; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Choroid Hemorrhage; Drug T	2002
Tissue factor and tissue factor pathway inhibitor levels in unstable angina patients during short-term low-molecular-weight heparin administration. British journal of haematology, 2002, Volume: 117, Issue:3 Topics: Adult; Aged; Angina, Unstable; Anticoagulants; Antithrombin III; Drug Administration Schedule; Enoxa	2002
Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. American heart journal, 2002, Volume: 143, Issue:5 Topics: Age Factors; Aged; Angina, Unstable; Area Under Curve; Aspirin; Biomarkers; Body Weight; Coronary Ar	2002
Unstable angina guidelines expand use of clopidogrel, enoxaparin. Geriatrics, 2002, Volume: 57, Issue:5 Topics: Angina, Unstable; Clopidogrel; Enoxaparin; Fibrinolytic Agents; Humans; Platelet Aggregation Inhibit	2002
The RITA 3 trial. Lancet (London, England), 2002, Dec-14, Volume: 360, Issue:9349 Topics: Aged; Angina, Unstable; Anticoagulants; Clinical Trials as Topic; Dalteparin; Humans; Myocardial Inf	2002
The use of low molecular weight heparin to predict clinical outcome in patients with unstable angina that had undergone percutaneous coronary intervention. The Korean journal of internal medicine, 2003, Volume: 18, Issue:3 Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Angiography; Coronary Res	2003
An acute inflammatory reaction induced by myocardial damage is superimposed on a chronic inflammation in unstable coronary artery disease. American heart journal, 2005, Volume: 149, Issue:4 Topics: Abciximab; Adult; Aged; Angina, Unstable; Antibodies, Monoclonal; Anticoagulants; Aspirin; C-Reactiv	2005
[Use of fragmin (low-molecular-weight heparin) in patients with unstable angina]. Klinicheskaia meditsina, 1994, Volume: 72, Issue:1 Topics: Aged; Angina, Unstable; Blood Platelets; Dalteparin; Factor Xa; Female; Fibrinolysis; Hemostasis; Hu	1994
Increasing the stability of unstable angina. Archives of internal medicine, 1997, Jan-27, Volume: 157, Issue:2 Topics: Angina, Unstable; Anticoagulants; Aspirin; Dalteparin; Drug Therapy, Combination; Humans; Treatment	1997
Unfractionated heparin dosing in the FRIC study. Circulation, 1998, Apr-14, Volume: 97, Issue:14 Topics: Angina, Unstable; Anticoagulants; Dalteparin; Heparin; Humans; Prospective Studies	1998
Increased fibrinogen levels are associated with persistent Chlamydia pneumoniae infection in unstable coronary artery disease. European heart journal, 1998, Volume: 19, Issue:4 Topics: Angina, Unstable; Antibodies, Anti-Idiotypic; Anticoagulants; Biomarkers; C-Reactive Protein; Chlamy	1998
New trials of LMW heparins - light and heavy weight as good on short but what about longer distances? European heart journal, 1999, Volume: 20, Issue:21 Topics: Angina, Unstable; Anticoagulants; Dalteparin; Heparin, Low-Molecular-Weight; Humans; Myocardial Infa	1999
[Dalteparin in the acute phase of unstable angina and non-Q-wave infarction]. Revista espanola de cardiologia, 2000, Volume: 53, Issue:8 Topics: Acute Disease; Angina, Unstable; Dalteparin; Fibrinolytic Agents; Humans; Myocardial Infarction	2000
Dalteparin for unstable angina and non-Q-wave myocardial infarction. Archives of internal medicine, 2000, Nov-13, Volume: 160, Issue:20 Topics: Angina, Unstable; Dalteparin; Electrocardiography; Fibrinolytic Agents; Humans; Myocardial Infarctio	2000
Acute coronary syndromes: extending medical intervention for five days before proceeding to revascularization. The American journal of cardiology, 2000, Dec-28, Volume: 86, Issue:12B Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Angiography; Coronary Art	2000
Evaluating the place of low-molecular-weight heparin in the management of acute coronary syndromes. A panel discussion with audience participation. Clinical cardiology, 2001, Volume: 24, Issue:3 Suppl Topics: Angina, Unstable; Anticoagulants; Atrial Fibrillation; Dalteparin; Heparin, Low-Molecular-Weight; Hu	2001
Antithrombotic treatment in patients with unstable coronary artery disease undergoing CABG. The Annals of thoracic surgery, 2001, Volume: 71, Issue:5 Topics: Angina, Unstable; Clinical Trials as Topic; Coronary Artery Bypass; Dalteparin; Drug Administration	2001

dalteparin and Angina at Rest